Aethlon Medical AEMD Commences Coverage by StockNews.com Analysts

As of Sunday, investment analysis firm StockNews.com commenced coverage on Aethlon Medical AEMD, a San Diego-based, medical technology company. The company, which is focused on developing therapeutic products aimed at treating serious infectious diseases and cancer, has recently had its stock coverage initiated with a 'sell' rating. In contrast, separate analyses saw a reduction in price target by HC Wainwright from $90.00 to $23.00, though they still maintained a 'buy' rating on AEMD.

Aethlon Medical's Stock Performance

AEMD stock opened at $1.72 on the preceding Friday, presenting a moderate decline of 7.0%. The company's market capitalization stands at approximately $4.27 million, with a negative PE ratio of -0.32 and a beta of 1.39. Recently, AEMD has been trading below its 50-day moving average of $2.01 and its 200-day average of $2.96, signaling a downturn after reaching a 1-year high of $8.70.

Recent Earnings and Analyst Expectations

The latest quarterly earnings report for Aethlon Medical revealed a loss of ($1.30) per share, a shortfall compared to the consensus estimate of a ($1.20) loss per share. This result also reflected a decrease from the previous year's loss of ($1.90) per share. Analysts project that AEMD will report a negative earnings per share (EPS) of -5.45 for the current fiscal year.

Institutional Movements

In the league of institutional investors, Vanguard Group Inc. upped their stake in AEMD by a remarkable 112.9% in the third quarter, now owning 1,053,198 shares worth about $613,000. Notably, Renaissance Technologies LLC increased its holdings by 11.6%, Jane Street Group LLC by 895.7%, Two Sigma Investments LP by 219.3%, and Citadel Advisors LLC initiated a new position. These investments underscore a pattern of increased institutional attention toward Aethlon Medical.

About Aethlon Medical

Aethlon Medical, Inc. AEMD is at the forefront of therapeutic technology developments, with its principal product being the Aethlon Hemopurifier—a clinical-stage immunotherapeutic device. Designed to extract life-threatening viruses and tumor-derived exosomes from the circulatory system, this device holds promise for mitigating the impacts of severe infectious diseases and cancers. The ongoing research and development activities pivot the company's standing in the therapeutic sector potentially enhancing its prospects for future growth and investment viability.

Aethlon, Medical, StockNews, Coverage, Sell, Buy, Target, Performance, Earnings, PE, Beta, Institutional, Investment, Hemopurifier, Technology, Diseases, Cancer